A Phase I Study of FHD-286 in People with Uveal Melanoma

Share
Print

Full Title

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286 in Subjects with Metastatic Uveal Melanoma

Purpose

The purpose of this study is to find the highest dose of the investigational drug FHD-286 that can be given in patients with melanoma of the eye (uveal melanoma) that has metastasized. FHD-286 works by blocking two proteins (BRG1 and BRM) that promote tumor growth. It is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic uveal melanoma.
  • Patients should recover from the serious side effects of prior therapies before receiving FHD-286.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alexander Shoushtari at 646-888-4161.

Protocol

21-295

Phase

I

Co-Investigators